Autolus Therapeutics plc announced its financial results for the year ended December 31, 2025, reporting AUCATZYL net product revenue of $74.3 million for the full year and providing a 2026 revenue outlook of $120 million to $135 million. The company also provided updates on its clinical pipeline, including progress in pediatric ALL, lupus nephritis, and progressive multiple sclerosis trials.
Key takeaways
Reported AUCATZYL net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year 2025.
Projects 2026 AUCATZYL net product revenue of $120 million to $135 million and expects to shift to positive gross margin in 2026.
AUCATZYL launched in the UK in January 2026 following a successful NICE evaluation.
Real-world data from the ROCCA consortium, covering approximately 60% of U.S. commercial patients, confirmed high clinical activity and favorable safety for AUCATZYL.
Obe-cel demonstrated a 95.5% overall response rate in pediatric r/r B-ALL patients in the CATULUS Phase 1 trial.
Cash, cash equivalents, and marketable securities totaled $300.7 million as of December 31, 2025, which is expected to fund operations into Q4 2027.